Aceragen (FRA:V9Z) Capital Expenditure : €0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is Aceragen Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Aceragen's cash flow for capital expenditures for the three months ended in Mar. 2023 was €0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2023 was €0.00 Mil.

Aceragen Capital Expenditure Historical Data

The historical data trend for Aceragen's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Capital Expenditure Chart

Aceragen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capital Expenditure

Get a 7-Day Free Trial

-0.07

-0.01

Aceragen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Capital Expenditure	Get a 7-Day Free Trial															-	-	-	-	-

Aceragen Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aceragen (FRA:V9Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (FRA:V9Z) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341

Website

https://www.aceragen.com

Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Aceragen (FRA:V9Z) Headlines

No Headlines